A Phase 3 interventional study of Mirikizumab in Crohn's Disease, sponsored by Eli Lilly and Company. Active, not recruiting at 322 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-11.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing mirikizumab in Crohn Disease — 7 open to participants now, 8 under way, 3 of them phase 3. mirikizumab · Crohn Disease.
Among the 10 studies testing mirikizumab in Crohn Disease, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 4 in phase 3, and was the 3rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →7 of the 10 studies testing mirikizumab in Crohn Disease are open now, in 12 countries. Recruiting first, the newest first:
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives · Sites in France
Ages 18–75
Alimentiv Inc. · Sites in United States, Canada
Ages 18+
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–17
Eli Lilly and Company · Sites in United States, Austria, Belgium and 13 more countries
Ages 2–19
Specialty Networks Research. · Sites in United States
Ages 21+
By country, each count listing its studies:
mirikizumab: first FDA approval 2023 (OMVOH), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2020.
This study's enrollment of 996 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 150 across the 10 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
10 studies in Crohn Disease by Eli Lilly and Company: 6 open now, 7 under way, 4 of them phase 3. Of 3 finished, 2 (67%) have results posted.
Among the 10 studies in Crohn Disease by Eli Lilly and Company, this one is the 2nd largest by enrollment, is the only one that started in 2020, is one of 5 in phase 3, and was the 3rd registered.
Eli Lilly and Company’s Crohn Disease studies by the year they started, since 2016.
2 of the studies testing mirikizumab in Crohn Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06997965Alimentiv Inc.Open-label Single-arm Study to Assess the Efficacy of Mirikizumab in Patients With Inflammatory Strictures Due to CD | 2027-09-01 |
| NCT07292012Groupe d'Etude Therapeutique des Affections Inflammatoires DigestivesEfficacy of MIrikizumab to Achieve Transmural Healing in patiENTs With Crohn's Disease | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies testing mirikizumab in Crohn Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 10 in Crohn Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Participants with a history of active TB with documentation of treatment by the Centers for Disease Control (CDC) and/or World Health Organization (WHO) criteria prior to the originator study are not excluded from the study.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to mirikizumab in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 milligrams (mg) subcutaneously (SC) every 4 weeks (Q4W) for 52 weeks.
Drug: Mirikizumab
Participants assigned to mirikizumab in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg intravenously (IV) Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to placebo in Study AMAM who switched from placebo to mirikizumab at week 12 and achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to placebo in Study AMAM who switched from placebo to mirikizumab at week 12 and did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to ustekinumab in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to ustekinumab in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to placebo in Study AMAM who achieved Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants assigned to placebo in Study AMAM who did not achieve Endoscopic Response at Week 52 of AMAM continued into Study AMAX and received mirikizumab 900 mg IV Q4W for 3 doses, followed by mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Participants from Study AMAG who continued into Study AMAX received mirikizumab 300 mg SC Q4W for 52 weeks.
Drug: Mirikizumab
Administered Q4W
Also known as: LY3074828
Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study)
Endoscopic Response defined as ≥50% reduction from AMAM study baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study)
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) total score \< (less than) 150. The CDAI measures the severity of active disease using 8 disease variables: stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations, presence or absence of fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight. Each variable is assigned a specific weight/multiplier, and the weighted values are summed to produce a CDAI total score. CDAI total scores can range from 0 to 600, with higher scores indicating more severe disease.
Time frame: Week 52
Percentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study)
Alternate endoscopic remission is defined as SES-CD Total Score ≤4 with at least a 2-point reduction from the AMAM study baseline and no subscore \>1. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no individual assessment score \>1 across all 20 individual assessments.
Time frame: Week 52
Percentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study)
Clinical response by Patient Reported Outcome (PRO) was defined as a ≥30% decrease from baseline in stool frequency (SF) and/or abdominal pain (AP) score, with neither symptom worsening from baseline. SF was measured as the number of liquid or very soft stools per day. AP was scored daily on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
Time frame: Week 52
Fecal Calprotectin at Week 12 (Participants Originating From AMAM Study)
Fecal calprotectin is an indicator of inflammation in the intestines with higher levels indicative of higher levels of inflammation.
Time frame: Week 12
C-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study)
C-Reactive Protein is a biomarker of systemic inflammation measured in the blood, with elevated levels indicating increased inflammatory activity in the body.
Time frame: Week 12
Change From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study)
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item participant completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Total scores range from 32 to 224; a higher score indicates a better quality of life.
Time frame: Baseline, Week 52
Eligibility for Study I6T-MC-AMAX (AMAX; NCT04232553) required completion of one of the originating studies: either Study I6T-MC-AMAM (AMAM; NCT03926130) or Study I6T-MC-AMAG (AMAG; NCT02891226). Participants from Study AMAM were classified as having achieved Endoscopic Response if they achieved a reduction from baseline in the Simple Endoscopic Score for Crohn's Disease \[SES-CD\] total score of greater than or equal to (\>=) 50% at Week 52.
| Milestone | AMAM Mirikizumab (Miri): Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM Placebo (PBO)/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Ustekinumab (Uste): Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|
| Started | 287 | 222 | 29 | 34 | 138 | 109 | 18 | 53 | 106 |
| Received at least one dose of study drug | 287 | 222 | 29 | 34 | 138 | 109 | 18 | 53 | 106 |
| Completed | 275 | 209 | 28 | 31 | 133 | 106 | 18 | 51 | 104 |
| Not completed | 12 | 13 | 1 | 3 | 5 | 3 | 0 | 2 | 2 |
| Withdrew: Adverse event | 3 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Other - as reported by the investigator | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 7 | 5 | 0 | 0 | 2 | 2 | 0 | 2 | 0 |
Endoscopic Response defined as ≥50% reduction from AMAM study baseline in Simple Endoscopic Score for Crohn's Disease (SES-CD) total score. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease.
| percentage of participants | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Endoscopic Response at Week 52 (Participants Originating From AMAM Study) | 82.1 (77.4 to 86.8) | 29.7 (23.0 to 36.4) | 92.6 (82.7 to 100) | 38.7 (23.7 to 56.2) | 75.0 (67.3 to 82.7) | 39.7 (29.6 to 49.8) | 94.1 (82.6 to 100) | 51.4 (36.9 to 65.8) |
Clinical remission was defined as a Crohn's Disease Activity Index (CDAI) total score \< (less than) 150. The CDAI measures the severity of active disease using 8 disease variables: stool frequency, severity of abdominal pain, degree of general well-being, presence or absence of extra-intestinal manifestations, presence or absence of fistula, use or non-use of antidiarrheal agents, presence or absence of an abdominal mass, hematocrit, and body weight. Each variable is assigned a specific weight/multiplier, and the weighted values are summed to produce a CDAI total score. CDAI total scores can range from 0 to 600, with higher scores indicating more severe disease.
| percentage of participants | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Remission at Week 52 (Participants Originating From AMAM Study) | 79.2 (74.1 to 84.4) | 65.9 (58.8 to 72.9) | 76.6 (60.1 to 93.2) | 55.9 (37.6 to 74.2) | 75.8 (67.9 to 83.6) | 74.6 (65.2 to 84.0) | 84.9 (65.3 to 100) | 68.5 (53.8 to 83.1) |
Alternate endoscopic remission is defined as SES-CD Total Score ≤4 with at least a 2-point reduction from the AMAM study baseline and no subscore \>1. The SES-CD evaluates 4 endoscopic variables (presence/size of ulcers, extent of ulcerated surface, extent of affected surface, and presence/severity of stenosis) across 5 ileocolonic bowel segments (ileum, right colon, transverse colon, left colon, and rectum), with each of the 4 variables scored from 0 (best) to 3 (worst) per segment, resulting in 20 individual assessments. Total SES-CD score is the sum of all 20 individual assessment scores across all the bowel segments. Scores range from 0 to 56, with higher scores indicating more severe disease. No subscore \>1 is defined as no individual assessment score \>1 across all 20 individual assessments.
| percentage of participants | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Alternate Endoscopic Remission at Week 52 (Participants Originating From AMAM Study) | 54.6 (48.4 to 60.7) | 14.2 (9.1 to 19.3) | 66.3 (48.0 to 84.5) | 25.8 (13.7 to 43.2) | 47.1 (38.3 to 56.0) | 22.1 (13.5 to 30.6) | 63.1 (39.6 to 86.6) | 32.6 (19.0 to 46.1) |
Clinical response by Patient Reported Outcome (PRO) was defined as a ≥30% decrease from baseline in stool frequency (SF) and/or abdominal pain (AP) score, with neither symptom worsening from baseline. SF was measured as the number of liquid or very soft stools per day. AP was scored daily on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, and 3 = severe.
| percentage of participants | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Percentage of Participants Achieving Clinical Response by Patient Reported Outcome (PRO) at Week 52 - (Participants Originating From AMAM Study) | 87.3 (83.1 to 91.4) | 74.7 (68.4 to 81.0) | 88.9 (76.8 to 100) | 63.3 (45.7 to 81.0) | 86.2 (80.1 to 92.3) | 84.0 (76.6 to 91.5) | 97.8 (86.4 to 100) | 78.2 (66.0 to 90.3) |
Fecal calprotectin is an indicator of inflammation in the intestines with higher levels indicative of higher levels of inflammation.
| micrograms per gram (μg/g) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Fecal Calprotectin at Week 12 (Participants Originating From AMAM Study) | 110.5 (37.0 to 293.0) | 310.0 (104.0 to 962.0) | 134.0 (15.0 to 484.0) | 168.0 (62.0 to 761.0) | 113.0 (40.0 to 364.0) | 312.5 (85.0 to 834.0) | 46.0 (15.0 to 415.0) | 333.5 (67.0 to 984.0) |
C-Reactive Protein is a biomarker of systemic inflammation measured in the blood, with elevated levels indicating increased inflammatory activity in the body.
| milligram per liter (mg/L) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| C-Reactive Protein (CRP) at Week 12 (Participants Originating From AMAM Study) | 1.4 (0.6 to 4.6) | 2.7 (1.1 to 5.4) | 1.4 (1.0 to 5.0) | 3.2 (1.1 to 6.2) | 1.3 (0.6 to 3.8) | 3.5 (0.9 to 6.8) | 2.3 (0.4 to 4.7) | 3.7 (1.3 to 7.3) |
The Inflammatory Bowel Disease Questionnaire (IBDQ) is a 32-item participant completed questionnaire that measures 4 aspects of patients' lives: symptoms directly related to the primary bowel disturbance (10 items), systemic symptoms (5 items), emotional function (12 items), and social function(5 items). Responses are graded on a 7-point Likert scale in which 7 denotes "not a problem at all" and 1 denotes "a very severe problem." IBDQ total score is calculated as the sum of all questions. Total scores range from 32 to 224; a higher score indicates a better quality of life.
| score on a scale | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC |
|---|---|---|---|---|---|---|---|---|
| Change From Baseline in Health Related Quality of Life at Week 52 : Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score (Participants Originating From AMAM Study) | 57.3 ± 1.99 | 46.1 ± 2.32 | 47.4 ± 6.12 | 38.6 ± 5.81 | 50.5 ± 2.82 | 49.9 ± 3.29 | 65.3 ± 7.84 | 46.4 ± 4.62 |
Collected over Baseline Up to Week 52. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AMAM Miri: Miri 300 mg SC | 0/287 (0%) | 19/287 (6.6%) | 189/287 (65.9%) |
| AMAM Miri: Miri 900 mg IV Then 300 mg SC | 1/222 (0.5%) | 20/222 (9%) | 138/222 (62.2%) |
| AMAM PBO/Miri: Miri 300 mg SC | 0/29 (0%) | 1/29 (3.4%) | 16/29 (55.2%) |
| AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | 1/34 (2.9%) | 8/34 (23.5%) | 21/34 (61.8%) |
| AMAM Uste: Miri 300 mg SC | 0/138 (0%) | 9/138 (6.5%) | 82/138 (59.4%) |
| AMAM Uste: Miri 900 mg IV Then 300 mg SC | 0/109 (0%) | 9/109 (8.3%) | 69/109 (63.3%) |
| AMAM PBO: Miri 300 mg SC | 0/18 (0%) | 0/18 (0%) | 12/18 (66.7%) |
| AMAM PBO: Miri 900 mg IV Then 300 mg SC | 0/53 (0%) | 7/53 (13.2%) | 33/53 (62.3%) |
| All AMAG Participants: Miri 300 mg SC | 0/106 (0%) | 3/106 (2.8%) | 68/106 (64.2%) |
| Event | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 2/287 | 1/222 | 0/29 | 3/34 | 3/138 | 2/109 | 0/18 | 1/53 | 1/106 |
| Ileal stenosisGastrointestinal disorders | 0/287 | 0/222 | 0/29 | 0/34 | 0/138 | 0/109 | 0/18 | 2/53 | 0/106 |
| Cerebrovascular accidentNervous system disorders | 0/287 | 0/222 | 1/29 | 0/34 | 0/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| Small intestinal obstructionGastrointestinal disorders | 0/287 | 1/222 | 0/29 | 1/34 | 1/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| Post procedural infectionInfections and infestations | 0/287 | 0/222 | 0/29 | 1/34 | 0/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| Transaminases increasedInvestigations | 0/287 | 0/222 | 0/29 | 1/34 | 0/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| ArthropathyMusculoskeletal and connective tissue disorders | 0/287 | 0/222 | 0/29 | 1/34 | 0/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| Rotator cuff syndromeMusculoskeletal and connective tissue disorders | 0/287 | 0/222 | 0/29 | 1/34 | 0/138 | 0/109 | 0/18 | 0/53 | 0/106 |
| Anal fistulaGastrointestinal disorders | 0/287 | 0/222 | 0/29 | 0/34 | 1/138 | 0/109 | 0/18 | 1/53 | 0/106 |
| IleusGastrointestinal disorders | 0/287 | 1/222 | 0/29 | 0/34 | 0/138 | 0/109 | 0/18 | 1/53 | 0/106 |
| Event | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19Infections and infestations | 35/287 | 25/222 | 2/29 | 2/34 | 12/138 | 14/109 | 5/18 | 7/53 | 12/106 |
| DiarrhoeaGastrointestinal disorders | 9/287 | 9/222 | 0/29 | 0/34 | 2/138 | 4/109 | 2/18 | 0/53 | 2/106 |
| NasopharyngitisInfections and infestations | 19/287 | 0/222 | 2/29 | 0/34 | 7/138 | 5/109 | 2/18 | 5/53 | 6/106 |
| HeadacheNervous system disorders | 10/287 | 8/222 | 0/29 | 0/34 | 3/138 | 4/109 | 0/18 | 2/53 | 11/106 |
| AlopeciaSkin and subcutaneous tissue disorders | 1/287 | 1/222 | 3/29 | 0/34 | 1/138 | 1/109 | 0/18 | 0/53 | 1/106 |
| Vulvovaginal candidiasisInfections and infestations | 0/124 | 1/88 | 0/17 | 1/11 | 0/70 | 0/54 | 0/7 | 0/21 | 0/49 |
| EndometriosisReproductive system and breast disorders | 0/124 | 0/88 | 0/17 | 1/11 | 0/70 | 0/54 | 0/7 | 0/21 | 0/49 |
| AnaemiaBlood and lymphatic system disorders | 10/287 | 4/222 | 1/29 | 3/34 | 7/138 | 4/109 | 1/18 | 2/53 | 1/106 |
| Penile painReproductive system and breast disorders | 0/163 | 0/134 | 1/12 | 0/23 | 0/68 | 0/55 | 0/11 | 0/32 | 0/57 |
| ProstatitisReproductive system and breast disorders | 1/163 | 0/134 | 1/12 | 0/23 | 0/68 | 0/55 | 0/11 | 0/32 | 0/57 |
All enrolled participants.
| Age, Continuous(years) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 37.2 ± 12.84 | 38.4 ± 13.66 | 39.5 ± 16.00 | 37.7 ± 11.92 | 39.2 ± 12.84 | 37.6 ± 12.68 | 37.6 ± 9.52 | 38.0 ± 12.88 | 41.5 ± 12.20 | 38.4 ± 12.98 |
| Sex: Female, Male(Participants) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Female | 124 | 88 | 17 | 11 | 70 | 54 | 7 | 21 | 49 | 441 |
| Male | 163 | 134 | 12 | 23 | 68 | 55 | 11 | 32 | 57 | 555 |
| Race (NIH/OMB)(Participants) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 2 | 0 | 6 |
| Asian | 68 | 61 | 7 | 5 | 31 | 21 | 3 | 6 | 13 | 215 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 4 | 5 | 0 | 1 | 3 | 3 | 0 | 0 | 7 | 23 |
| White | 207 | 154 | 21 | 26 | 102 | 84 | 14 | 45 | 85 | 738 |
| More than one race | 2 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4 |
| Unknown or Not Reported | 5 | 1 | 1 | 2 | 0 | 0 | 1 | 0 | 0 | 10 |
| Region of Enrollment(Participants) | AMAM Miri: Miri 300 mg SC | AMAM Miri: Miri 900 mg IV Then 300 mg SC | AMAM PBO/Miri: Miri 300 mg SC | AMAM PBO/Miri: Miri 900 mg IV Then 300 mg SC | AMAM Uste: Miri 300 mg SC | AMAM Uste: Miri 900 mg IV Then 300 mg SC | AMAM PBO: Miri 300 mg SC | AMAM PBO: Miri 900 mg IV Then 300 mg SC | All AMAG Participants: Miri 300 mg SC | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Argentina | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Australia | 3 | 4 | 0 | 1 | 0 | 0 | 0 | 4 | 1 | 13 |
| Austria | 1 | 5 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 9 |
| Belgium | 2 | 3 | 0 | 1 | 0 | 1 | 0 | 1 | 3 | 11 |
| Brazil | 14 | 11 | 0 | 3 | 7 | 7 | 2 | 3 | 0 | 47 |
| Canada | 11 | 4 | 4 | 0 | 5 | 3 | 1 | 1 | 0 | 29 |
| China | 34 | 32 | 5 | 4 | 10 | 16 | 0 | 4 | 0 | 105 |
| Croatia | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 |
| Czechia | 12 | 14 | 5 | 2 | 8 | 7 | 2 | 2 | 6 | 58 |
| France | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Germany | 15 | 4 | 1 | 0 | 2 | 5 | 2 | 2 | 0 | 31 |
| Hungary | 10 | 3 | 1 | 1 | 5 | 5 | 1 | 1 | 4 | 31 |
| India | 4 | 6 | 1 | 0 | 5 | 1 | 0 | 0 | 0 | 17 |
| Israel | 3 | 1 | 0 | 0 | 0 | 1 | 0 | 3 | 0 | 8 |
| Italy | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Japan | 6 | 5 | 0 | 1 | 9 | 2 | 0 | 1 | 13 | 37 |
| Latvia | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Lithuania | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 4 |
| Mexico | 3 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 7 |
| Netherlands | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 5 | 8 |
| Poland | 40 | 33 | 0 | 4 | 17 | 22 | 2 | 8 | 16 | 142 |
| Romania | 5 | 5 | 0 | 0 | 1 | 1 | 1 | 0 | 4 | 17 |
| Russia | 18 | 18 | 2 | 5 | 11 | 5 | 1 | 8 | 6 | 74 |
| Serbia | 4 | 1 | 4 | 2 | 3 | 2 | 0 | 2 | 0 | 18 |
| Slovakia | 3 | 4 | 0 | 0 | 3 | 3 | 0 | 1 | 0 | 14 |
| South Korea | 21 | 17 | 1 | 0 | 6 | 2 | 3 | 1 | 0 | 51 |
| Switzerland | 2 | 1 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 6 |
| Turkey | 15 | 9 | 1 | 1 | 1 | 5 | 0 | 2 | 0 | 34 |
| Ukraine | 22 | 11 | 2 | 3 | 18 | 11 | 2 | 1 | 13 | 83 |
| United Kingdom | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| United States | 26 | 26 | 1 | 3 | 19 | 7 | 1 | 6 | 35 | 124 |
Showing the first 100 of 322 sites across 32 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jun 2020 to primary completion in Nov 2024, 53 months.
Results were first posted in Dec 2025, 1 year after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 53 months is above that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab